肠源性脂多糖的研究进展
| 作者: |
1杨喜艳,
1卢放根
1 中南大学湘雅二医院消化内科，长沙 410011 |
| 通讯: |
卢放根
Email: Lufanggenyao@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2013.05.012 |
摘要
成人肠道内约有1013~1014 个共生菌，脂多糖(lipopolysaccharide，LPS) 是革兰阴性细菌细胞壁的组成部分，也是革兰阴性菌感染的主要致病分子。近年来研究发现肠源性LPS 是慢性非感染性疾病如代谢综合征等的致病因素之一。因此，LPS 与人类健康的关系受到高度重视。近年来一些研究探讨了肠源性LPS 的结构功能、吸收代谢及与低度炎症综合征的关系、如何降低肠源性的LPS进入血液循环以及内毒素血症的治疗措施，本文对此作一综述。
关键词：
内毒素
脂多糖
碱性磷酸酶
低度炎症
高脂饮食
Advances in study on gut-derived lipopolysaccharide
DOI: 10.3978/j.issn.2095-6959.2013.05.012
Abstract
There are about 1013–1014 intestinal commensal bacteria in normal adult. LPS is a major component in Gramnegative bacterial cell walls, which is the main pathogenic molecule of Grame-negative bacteria. In recent years, it has been suggested that gut-derived LPS is one of the pathogenic factors in chronic non-infectious diseases, such as metabolic syndrome. Therefore, LPS is closely related to human health. In this article, we reviewed the structure and function, absorption and metabolism of gut-derived LPS, and the relation with low grade inflammation. How to decrease the gut-derived LPS into blood circulation and how to treat endotoxemia are also included in this review.